# AusperBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ausperbio

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.ausperbio.com
- Total disclosed funding: $343M
- Latest round: Series C (Aug 28, 2026)
- Investors on record: 10

## About

Based in Zhejiang, China, and founded in 2019, AusperBio Therapeutics Inc., or Ausper Biopharma Co., Ltd., trading as AusperBio, focuses on intrahepatic and extrahepatic targeted therapy. The company has acquired Med-Oligo ASO independent intellectual property rights. In August 2026, AusperBio raised USD 120 million in Series C funding led by an investor, with participation from RA Capital Management, Sherpa Healthcare Partners, Hankang Capital, Suzhou Xincheng Private Equity Fund Management, Qiming Venture Partners, YuanBio Venture, CDH Investments, and other investors.

The company develops the Med Oligo™ small nucleic acid drug platform, hepatitis B therapeutic vaccine platform, and nasal spray antibody platform. Its R&D drug includes AHB-137, which is a naked antisense oligonucleotide (ASO). And AHB-137 can treat and prevent chronic hepatitis B and other infectious diseases.

The company generates revenue by developing and commercializing oligonucleotide-based therapeutics, advancing its proprietary clinical-stage drug pipeline, and generating revenue through strategic partnerships, licensing agreements, research collaborations, and the future commercialization of treatments targeting hepatitis B, infectious diseases, cancer immunotherapy, and muscle disorders.

The Series C funding raised in August 2026 will primarily be used to support the Phase III registration clinical trial and commercialization preparation for AHB-137, accelerate the development of AHB-171 and next-generation combination therapies, and further expand the company's innovative oligonucleotide product pipeline.

## Funding rounds

- Series C, Aug 28, 2026, $120M — CDH Investments, Qiming Venture Partners, RA Capital Management, YuanBio Venture, Hankang Capital, Sherpa Healthcare Partners, Suzhou Xincheng Private Equity Fund Management
- Series B, Sep 21, 2025, $63M — CDH Investments, Qiming Venture Partners, YuanBio Venture, Genesis Capital, Hankang Capital, Sherpa Healthcare Partners
- Series B, May 29, 2025, $50M — CDH Investments, Qiming Venture Partners, YuanBio Venture, Genesis Capital, Hankang Capital, Sherpa Healthcare Partners
- Series B, Dec 27, 2024, $73M — CDH Investments, Qiming Venture Partners, Sherpa Capital, YuanBio Venture, Hankang Capital, InnoPinnacle Fund
- Series A, Jul 14, 2024, $37M — Qiming Venture Partners, YuanBio Venture, Genesis Capital, Hankang Capital, InnoPinnacle Fund

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B, Series C
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A, Series B, Series C
- Genesis Capital — Series A, Series B
- Hankang Capital (https://capitalatlas.ai/funds/hankang-capital) — Series A, Series B, Series C
- InnoPinnacle Fund — Series A, Series B
- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Series B, Series C
- Sherpa Capital (https://capitalatlas.ai/funds/sherpa-capital) — Series B
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series B, Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- Suzhou Xincheng Private Equity Fund Management (https://capitalatlas.ai/funds/suzhou-xincheng-private-equity-fund-management) — Series C